報價延遲最少15分鐘:2026/06/03 14:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.7 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.30/-1.24
|
|
企業價值
125.32M
|
| 資產負債 |
|
每股賬面淨值
0.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
16.15M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO,formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity. |
